4.6 Article

Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct

期刊

ONCOIMMUNOLOGY
卷 11, 期 1, 页码 -

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2021.2012961

关键词

CD4; CD8; CD39; TIL; HCMV; cancer; tumor; infiltrating; bystander

资金

  1. Fred Hutchinson Cancer Research Center
  2. Andy Hill Endowment Distinguished Researcher CARE fund

向作者/读者索取更多资源

The study reveals the phenotypic heterogeneity of CD4(+) T cells in lung and colorectal cancers, which can also recognize cancer-unrelated antigens.
Tumor-specific T cells likely underpin effective immune checkpoint-blockade therapies. Yet, most studies focus on Treg cells and CD8(+) tumor-infiltrating lymphocytes (TILs). Here, we study CD4(+) TILs in human lung and colorectal cancers and observe that non-Treg CD4(+) TILs average more than 70% of total CD4(+) TILs in both cancer types. Leveraging high dimensional analyses including mass cytometry, we reveal that CD4(+) TILs are phenotypically heterogeneous, within each tumor and across patients. Consistently, we find different subsets of CD4(+) TILs showing characteristics of effectors, tissue resident memory (Trm) or exhausted cells (expressing PD-1, CTLA-4 and CD39). In both cancer types, the frequencies of CD39(-) non-Treg CD4(+) TILs strongly correlate with frequencies of CD39(-) CD8(+) TILs, which we and others have previously shown to be enriched for cells specific for cancer-unrelated antigens (bystanders). Ex-vivo, we demonstrate that CD39(-) CD4(+) TILs can be specific for cancer-unrelated antigens, such as HCMV epitopes. Overall, our findings highlight that CD4(+) TILs can also recognize cancer-unrelated antigens and suggest measuring CD39 expression as a straightforward way to quantify or isolate bystander CD4(+) T cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage

James Isaacs, Aaron C. Tan, Brent A. Hanks, Xiaofei Wang, Kouros Owzar, James E. Herndon, Scott J. Antonia, Steven Piantadosi, Mustafa Khasraw

Summary: This article discusses the application of clinical trials in immuno-oncology, highlighting the importance of primary outcomes based on pharmacokinetic or pharmacodynamic immunologic mechanisms. It also explores the underutilization of these trials and showcases how new technologies and translational approaches can be effectively used in developing different types of immunotherapeutic agents.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial

Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min-Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach

Summary: This study investigates the patient-reported outcomes of selpercatinib treatment in patients with RET fusion-positive NSCLC, with the majority showing stable or improved health-related quality of life during the treatment period. A significant percentage of patients experienced improvements in dyspnea and pain, suggesting potential therapeutic benefits.

ONCOLOGIST (2022)

Review Oncology

Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma

Kirit Singh, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, Susan M. Chang, Rifaquat Rahman, Evanthia Galanis, Alireza Mansouri, Vinay K. Puduvalli, David A. Reardon, Solmaz Sahebjam, John H. Sampson, John Simes, Donald A. Berry, Gelareh Zadeh, Tim F. Cloughesy, Minesh P. Mehta, Steven Piantadosi, Michael Weller, Amy B. Heimberger, Mustafa Khasraw

Summary: Immunotherapy has not shown significant improvement in outcomes for glioblastoma patients due to the multiple and unique mechanisms of immune evasion and escape in this highly heterogeneous tumor. Combinatorial approaches of immune-oriented therapy are required to overcome these mechanisms. The design of clinical trials evaluating these approaches needs careful consideration.

CLINICAL CANCER RESEARCH (2022)

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan, Daniel S. W. Tan

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Biotechnology & Applied Microbiology

Single-cell immunology of SARS-CoV-2 infection

Yuan Tian, Lindsay N. Carpp, Helen E. R. Miller, Michael Zager, Evan W. Newell, Raphael Gottardo

Summary: This review summarizes existing studies using single-cell technologies to investigate the immune responses and molecular mechanisms in COVID-19. Understanding the immune cell subsets and molecular factors associated with protective or pathological immunity may contribute to the development of vaccines and therapeutics for COVID-19. Single-cell technologies show promise in uncovering the heterogeneity of immune responses and pathogenesis mechanisms of COVID-19.

NATURE BIOTECHNOLOGY (2022)

Article Oncology

PD-L1 score as a prognostic biomarker in asian early- stage epidermal growth factor receptor-mutated lung cancer*

Stephanie P. L. Saw, Win Pin Ng, Siqin Zhou, Gillianne G. Y. Lai, Aaron C. Tan, Mei -Kim Ang, Wan-Teck Lim, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Wan Ling Tan, Tanujaa Rajasekaran, Johan W. K. Chan, Yi Lin Teh, Mengyuan Pang, Jia-Chi Yeo, Angela Takano, Boon-Hean Ong, Eng-Huat Tan, Sze Huey Tan, Anders J. Skanderup, Daniel S. W. Tan

Summary: The aim of this study was to compare the prognostic value of programmed death-ligand 1 (PD-L1) score in early-stage epidermal growth factor receptor (EGFR)-mutated and EGFR-wildtype non-small cell lung cancer (NSCLC). The results showed that PD-L1 > 1% was an independent predictor of worse prognosis in EGFR-mutated NSCLC and was associated with inferior disease-free survival (DFS) regardless of EGFR status. Therefore, PD-L1 score should be evaluated as a risk stratification factor in prospective adjuvant studies among EGFR-mutated NSCLC.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

Nicholas A. Vitanza, Ashley L. Wilson, Wenjun Huang, Kristy Seidel, Christopher Brown, Joshua A. Gustafson, Jason K. Yokoyama, Adam J. Johnson, Blake A. Baxter, Ryan W. Koning, Aquene N. Reid, Michael Meechan, Matthew C. Biery, Carrie Myers, Stephanie D. Rawlings-Rhea, Catherine M. Albert, Samuel R. Browd, Jason S. Hauptman, Amy Lee, Jeffrey G. Ojemann, Michael E. Berens, Matthew D. Dun, Jessica B. Foster, Erin E. Crotty, Sarah E. S. Leary, Bonnie L. Cole, Francisco A. Perez, Jason N. Wright, Rimas J. Orentas, Tony Chour, Evan W. Newell, Jeffrey R. Whiteaker, Lei Zhao, Amanda G. Paulovich, Navin Pinto, Juliane Gust, Rebecca A. Gardner, Michael C. Jensen, Julie R. Park

Summary: This study reports the first administration of repeatedly dosed intracranial B7-H3 CAR T cells for patients with DIPG, indicating tolerability, detection of CAR T cells in the CSF, elevation of CSF cytokines supporting locoregional immune activation, and the feasibility of serial mass spectrometry from both serum and CSF.

CANCER DISCOVERY (2023)

Editorial Material Oncology

Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma

Aaron C. Tan, Keigo Kobayashi, Stephanie P. L. Saw, Daniel S. W. Tan, Darren Wan-Teck Lim

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Review Biochemistry & Molecular Biology

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC

Keigo Kobayashi, Aaron C. Tan

Summary: The development of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. However, drug resistance remains a challenge in the long-term management of patients. This review highlights the role of intratumoral heterogeneity and drug-tolerant persister (DTP) cells in NSCLC resistance mechanisms. Changes in the tumor microenvironment, chromosomal instability, and extrachromosomal DNA (ecDNA) also contribute to intratumoral heterogeneity and drug resistance. Comprehensive genomic profiling has provided valuable insights into primary resistance mechanisms in the context of tumor heterogeneity. Understanding these mechanisms is crucial for developing individualized anticancer therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Immunology

CD4+ T cells expressing CX3CR1, GPR56, with variable CD57 are associated with cardiometabolic diseases in persons with HIV

Celestine N. Wanjalla, Curtis L. Gabriel, Hubaida Fuseini, Samuel S. Bailin, Mona Mashayekhi, Joshua Simmons, Christopher M. Warren, David R. Glass, Jared Oakes, Rama Gangula, Erin Wilfong, Stephen Priest, Tecla Temu, Evan W. Newell, Suman Pakala, Spyros A. Kalams, Sara Gianella, David Smith, David G. Harrison, Simon A. Mallal, John R. Koethe

Summary: People with HIV on long-term antiretroviral therapy have a higher risk of cardiometabolic diseases, partly due to persistent inflammation despite viral suppression. Immune responses to co-infections, such as cytomegalovirus, may contribute to these comorbidities and could be targeted for potential therapies.

FRONTIERS IN IMMUNOLOGY (2023)

Meeting Abstract Oncology

Cellular profiling of leukapheresis and infusion products of patients enrolled in CD19 CAR T cell therapy identifies biomarkers associated with clinical outcomes.

Tony Chour, Alexandre Hirayama, Ye Zheng, Alyssa Sheih, Summer Zhuang, Ashley Wilson, Vicky Wu, Raphael Gottardo, Cameron Turtle, Rebecca Gardner, Evan Newell

CANCER RESEARCH (2022)

Article Medicine, Research & Experimental

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin M. Blakely, Junji Suzuki, Yu-Ting Chou, Siraj M. Ali, D. Lucas Kerr, Victor R. Olivas, Jonathan Shue, Julia Rotow, Manasi K. Mayekar, Franziska Haderk, Nilanjana Chatterjee, Anatoly Urisman, Jia Chi Yeo, Anders J. Skanderup, Aaron C. Tan, Wai Leong Tam, Oscar Arrieta, Kazuyoshi Hosomichi, Akihiro Nishiyama, Seiji Yano, Yuriy Kirichok, Daniel S. W. Tan, Rafael Rosell, Ross A. Okimoto, Trever G. Bivona

Summary: This study investigates the impact of co-occurring genetic alterations on mutant EGFR and identifies the deficiency of RNA-binding factor RBM10 as a factor that decreases the efficacy of EGFR inhibitors in lung cancer treatment. The study reveals that RBM10 modulates tumor cell apoptosis by regulating the alternative splicing of Bcl-x and its deficiency diminishes EGFR inhibitor-mediated apoptosis. The findings suggest that co-occurring genetic alterations and splicing factor deficiency play a role in determining the sensitivity to targeted kinase inhibitor therapy.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Meeting Abstract Oncology

Single-cell analysis reveals clonally expanded CD57+CD8 T cells in periphery are associated with response to PD-L1 blockade in bladder cancer patients

Mahesh Yadav, Michael Fehlings, Leesun Kim, Xiangnan Guan, Kobe C. Yuen, Alireza Tafazzol, Deepali Rishipathak, Shomyesh Sanjabi, Andrew Wallace, Alessandra Nardin, Siming Ma, Ana Milojkovic, Evan Newell, Sanjeev Mariathasan

CANCER RESEARCH (2022)

暂无数据